

June 19, 2023

News Release

Company: Olympus Corporation
Stefan Kaufmann, Director, Representative Executive Officer, President and CEO
(Code: 7733, Prime, Tokyo Stock Exchange)
Contact: Takaaki Sakurai, Vice President, Investor Relations
TEL: +81-3-3340-2111

(Change of Disclosure Matters) Notice Regarding Acquisition of Korean Gastrointestinal Stent Company Taewoong Medical Co., Ltd. (to make it a subsidiary)

Olympus Corporation ("Olympus") announced in the timely disclosure of "Notice Regarding Acquisition of Korean Gastrointestinal Stent Company Taewoong Medical Co., Ltd. (to make it a subsidiary)" dated February 24, 2023 that we would acquire all outstanding shares of Taewoong Medical Co., Ltd., a Korean medical device manufacturer, on June 30, 2023, making it a wholly owned subsidiary. However, due to the fact that it is expected to take more time than anticipated for the closing conditions to be met, such as obtaining approvals from relevant authorities pursuant to the competition laws and related laws and regulations of Japan and other relevant jurisdictions, Olympus announces that the date of closing of share transfer is expected to occur by the end of March 2024 (planned).

The impact of postponement of the date of closing of share transfer on our consolidated financial forecasts is currently being examined, but we expect it to be immaterial. If any future event which requires disclosure arises, we will announce it promptly

(Reference) Consolidated financial results forecasts for the current fiscal year (released on May 12, 2023) and actual consolidated results for the previous fiscal year

(in million yen)

	Revenue	Operating profit	Profit before tax	Profit attributable to owners of parent
Current Forecast (FY ending March 2024)	914,000	163,000	159,000	336,000
Actual Results (FY ended March 2023)	881,923	186,609	182,294	143,432